PETX Aratana Therapeutics Inc

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Aratana Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Aratana Therapeutics, Inc securities (NASDAQ: PETX) from March 16, 2015 through February 3, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aratana investors under the federal securities laws.

To join the Aratana class action, go to http://rosenlegal.com/cases-1049.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (2) consequently, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors with respect to the likely timeline for a commercial launch of ENTYCE; and (4) as a result, Aratana’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1049.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

EN
07/02/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aratana Therapeutics Inc

GlobalData Department
  • GlobalData Department

Aratana Therapeutics Inc (PETX) - Pharmaceuticals & Healthcare - Deals...

Summary Aratana Therapeutics Inc (Aratana) is a provider of pet care solutions. The company develops, commercializing and markets biopharmaceutical products for medical condition in cats and dogs. Its pipeline portfolio consists of small molecule pharmaceuticals and large molecule biologics that aim for the treatment serious conditions in pets. Aratana offers products candidates, which include Galliprant (AT-001), for the treatment of osteoarthritis pain and inflammation; Entyce (AT-002), for a...

1 director sold

A director at Aratana Therapeutics Inc sold 75,000 shares at 6.057USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...

 PRESS RELEASE

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of a Class...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Aratana Therapeutics, Inc. (NASDAQ: PETX) between March 16, 2015 and February 3, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Dezi v. Aratana Therapeutics, Inc., et al. (Case No. 1:17-cv-01446) in the USDC for the Southern District of New York. To get more information go to: http://www.zlk.com/pslra/arat...

 PRESS RELEASE

PETX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors...

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Aratana Therapeutics, Inc. (NASDAQ: PETX) securities between March 16, 2015 and February 3, 2017. Click here to learn about the case: http://www.wongesq.com/pslra/aratana-therapeutics. There is no cost or obligation to you. According to the complaint, throughout the Class Period Defendants made false and/or misleading...

 PRESS RELEASE

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadli...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Aratana Therapeutics, Inc. (Nasdaq:PETX) (“Aratana” or the “Company”) securities during the period between March 16, 2015 and February 3, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 7, 2017...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch